Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Sellas Life Sciences Group aggregated by PharmaCompass.com.

    Client Virtual Booth

    SELLAS LIFE SCIENCES GROUP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Sellas Life Sciences Group
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Times Square Tower, 7 Times Square, Suite 2503, New York, NY 10036
    Telephone
    Telephone
    646-200-5278
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sellaslifesciences.com/Home/default.aspx
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    SELLAS Life Sciences Reports Full Year 2023 Financial Results
    SELLAS Life Sciences Reports Full Year 2023 Financial Results

    https://www.globenewswire.com/news-release/2024/03/28/2854454/0/en/SELLAS-Life-Sciences-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    28 Mar 2024
    Share Share
    SELLAS Announces Positive Data from the Phase 2a Study of SLS009 in r/r AML
    SELLAS Announces Positive Data from the Phase 2a Study of SLS009 in r/r AML

    https://www.globenewswire.com/news-release/2024/03/26/2852262/0/en/SELLAS-Announces-Positive-Topline-Data-from-the-Phase-2a-Study-of-SLS009-in-r-r-AML-and-Provides-Steering-Committee-Update-on-Phase-3-REGAL-Study.html

    GLOBENEWSWIRE
    26 Mar 2024
    Share Share
    SELLAS Life Sciences Group Announces Closing of $20 M RDO
    SELLAS Life Sciences Group Announces Closing of $20 M RDO

    https://www.globenewswire.com/news-release/2024/03/19/2848962/0/en/SELLAS-Life-Sciences-Group-Announces-Closing-of-20-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    19 Mar 2024
    Share Share
    SELLAS to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
    SELLAS to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

    https://www.globenewswire.com/news-release/2024/03/19/2848584/0/en/SELLAS-Life-Sciences-to-Host-Corporate-Update-Call-on-March-26-2024-at-8-15-am-ET.html

    GLOBENEWSWIRE
    19 Mar 2024
    Share Share
    SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering
    SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering

    https://www.globenewswire.com//news-release/2024/03/15/2847066/0/en/SELLAS-Life-Sciences-Group-Announces-20-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    15 Mar 2024
    Share Share
    SELLAS Announces Executive Leadership Reorganization
    SELLAS Announces Executive Leadership Reorganization

    https://www.globenewswire.com/news-release/2024/03/08/2843075/0/en/SELLAS-Announces-Executive-Leadership-Reorganization-and-Prioritization-of-Commercialization-Partnerships.html

    GLOBENEWSWIRE
    08 Mar 2024
    Share Share
    SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data
    SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data

    https://www.globenewswire.com//news-release/2024/03/01/2838804/0/en/SELLAS-Life-Sciences-Delivers-Oral-Presentation-of-SLS009-Phase-1-Data-for-Acute-Myeloid-Leukemia-Patients-at-2024-European-School-of-Haematology-ESH-Conference.html

    GLOBENEWSWIRE
    01 Mar 2024
    Share Share
    SELLAS Life to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients
    SELLAS Life to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients

    https://www.globenewswire.com//news-release/2024/02/29/2837938/0/en/SELLAS-Life-Sciences-to-Present-SLS009-Phase-1-Data-from-Acute-Myeloid-Leukemia-Patients-at-the-2024-European-School-of-Haematology-ESH-Conference-Updated-Date-and-Time.html

    GLOBENEWSWIRE
    29 Feb 2024
    Share Share
    SELLAS Announces Publication of Preclinical Data on its SLS009
    SELLAS Announces Publication of Preclinical Data on its SLS009

    https://www.globenewswire.com//news-release/2024/02/06/2824334/0/en/SELLAS-Announces-Publication-of-Preclinical-Data-on-its-Highly-Selective-CDK9-Inhibitor-SLS009-in-Oncotarget.html

    GLOBENEWSWIRE
    06 Feb 2024
    Share Share
    SELLAS Life to Present SLS009 Phase 1 from Acute Myeloid Leukemia Patients
    SELLAS Life to Present SLS009 Phase 1 from Acute Myeloid Leukemia Patients

    https://www.globenewswire.com//news-release/2024/01/25/2816797/0/en/SELLAS-Life-Sciences-to-Present-SLS009-Phase-1-Data-from-Acute-Myeloid-Leukemia-Patients-at-the-2024-European-School-of-Haematology-ESH-Conference.html

    GLOBENEWSWIRE
    25 Jan 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search